DNA 및 유전자 클로닝 서비스 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)

DNA and Gene Cloning Services Market Summary

Overview:

• The global DNA and gene cloning services market was valued at USD 4.20 billion in 2025 and is projected to reach USD 15.60 billion by 2034.
• The market is expected to expand at a CAGR of 15.7% during the forecast period 2026-2034, supported by the growth of biologics and gene-based therapeutics, the expansion of synthetic biology and cell and gene therapy, the advancement of gene synthesis and cloning technology, and the outsourcing of molecular biology to specialized service providers.
• By service type, the gene synthesis segment dominated the DNA and gene cloning services market with a 38% share in 2025.
• By application, the drug discovery and development segment dominated the DNA and gene cloning services market with a 36% share in 2025.
• By end-user, the pharmaceutical and biotechnology companies segment dominated the DNA and gene cloning services market with a 44% share in 2025.
• By grade, the research-use segment dominated the DNA and gene cloning services market with a 68% share in 2025.
• North America accounted for the largest share of the DNA and gene cloning services market at 41% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

DNA and gene cloning services are the outsourced molecular biology services that design, synthesize, clone, and construct genes, vectors, and DNA constructs for research, therapeutic, and industrial applications. The scope encompasses gene synthesis, in which custom DNA sequences are synthesized de novo; molecular cloning and subcloning, in which genes are inserted into vectors; vector construction and mutagenesis; plasmid preparation, codon optimization, and library construction. Leading providers include GenScript, which offers gene synthesis and cloning and subcloning into a large selection of vectors; Thermo Fisher Scientific, which offers GeneArt gene synthesis and Gateway cloning; Twist Bioscience, which offers silicon-chip DNA synthesis; Integrated DNA Technologies, which offers gene fragments; and Azenta through GENEWIZ, together with ATUM, Eurofins, Takara Bio, and other providers. The services free researchers from the labor of molecular biology and provide the building blocks of recombinant protein production, genome editing, vaccine development, and cell and gene therapy, and the contemporary market is defined by the growth of therapeutics and synthetic biology, the advance of synthesis technology, and the expansion of quality tiers from research-use to good manufacturing practice.

DNA and Gene Cloning Services Market Key Growth Drivers

• Growth of biologics and gene-based therapeutics, including monoclonal antibodies, messenger RNA vaccines, and gene therapies that begin with the cloning and expression of target sequences.
• Expansion of synthetic biology and cell and gene therapy, which depend on gene synthesis, cloning, and vector construction.
• Advances in gene synthesis and cloning technology, including silicon-chip synthesis, error correction, and automation that increase throughput and reduce cost.
• Outsourcing of molecular biology to specialized service providers with the expertise, capacity, and turnaround that researchers require.
• Growth of good manufacturing practice cloning and plasmid production for the clinical development of cell and gene therapy and vaccines.
• Growth of research funding and the demand for gene synthesis and cloning across academic and industrial research.
• Adoption of artificial intelligence and automated design platforms that optimize sequence design and cloning success.

Key Companies in DNA and Gene Cloning Services Market

The leading participants in the DNA and gene cloning services market include the following:

• GenScript Biotech Corporation
• Thermo Fisher Scientific Inc.
• Twist Bioscience Corporation
• Integrated DNA Technologies, Inc.
• Azenta, Inc.
• ATUM
• Eurofins Scientific SE
• Takara Bio Inc.
• Merck KGaA
• Macrogen, Inc.

Factors Contributing to the Growth of the DNA and Gene Cloning Services Market

Market Drivers

Growth of Biologics and Gene-Based Therapeutics

The foundational driver of the DNA and gene cloning services market is the growth of biologics and gene-based therapeutics, which begin with the cloning and expression of target sequences. Biologic and gene-based therapeutics, including monoclonal antibodies, recombinant proteins, messenger RNA vaccines, and gene therapies, have become a central and fast-growing part of the pharmaceutical pipeline, and these products begin with the cloning and expression of target genes in microbial or mammalian systems. The development of a biologic or gene-based therapeutic requires the synthesis and cloning of the target sequence, the construction of expression vectors, and the production of plasmid DNA, and DNA and gene cloning services provide these foundational steps. The growth of the biologics pipeline, the expansion of antibody, protein, and vaccine development, and the rise of gene and cell therapies increase the demand for gene synthesis, cloning, and vector construction that begin their development. Service providers offer gene synthesis, cloning, and expression solutions that accelerate the discovery and development of biologics and gene-based therapeutics, and the growth of these therapeutics drives the demand for the services. As biologics and gene-based therapeutics grow and as their pipelines expand, the demand for gene synthesis and cloning that begin their development grows in step. The growth of biologics and gene-based therapeutics anchors the growth of the DNA and gene cloning services market across the forecast period.

Expansion of Synthetic Biology and Cell and Gene Therapy

The expansion of synthetic biology and cell and gene therapy is a defining driver that depends on gene synthesis, cloning, and vector construction. Synthetic biology, which engineers biological systems for research, industrial, and therapeutic applications, depends on the synthesis and assembly of genes, pathways, and constructs, and cell and gene therapy depends on the synthesis and cloning of therapeutic genes, the construction of viral and non-viral vectors, and the production of plasmid DNA. The growth of synthetic biology, including metabolic engineering, protein and antibody engineering, and the construction of gene circuits and libraries, drives the demand for gene fragments, gene synthesis, and cloning, and gene fragments are used to develop metabolic pathways, build variant libraries, and assemble genome editing constructs. Cell and gene therapy, one of the fastest-growing areas of medicine, requires the synthesis and cloning of therapeutic sequences, the construction of vectors, and the production of clinical-grade plasmid DNA, and providers support the development of these therapies from research through clinical stages. The expansion of synthetic biology and cell and gene therapy, and their dependence on gene synthesis and cloning, drive the demand for services. As synthetic biology and cell and gene therapy expand, the demand for the gene synthesis, cloning, and vector construction they require grows. The expansion of synthetic biology and cell and gene therapy sustains demand for DNA and gene cloning services across the forecast period.

Market Restraints

The DNA and gene cloning services market faces several interrelated restraints that temper its growth. The foremost is the complexity and cost of high-value and clinical-grade services, since the synthesis of long, complex, and difficult sequences and the production of good manufacturing practice-grade DNA are technically challenging and costly, and the complexity and cost of these services can limit access and require substantial capability and investment. The requirement for biosecurity screening and export control adds obligation and complexity, since providers must screen synthetic gene sequences and customers for sequences of concern under the harmonized screening protocol of the International Gene Synthesis Consortium and the framework for nucleic acid synthesis screening, and the screening and compliance add cost and process. The technical challenges of synthesizing difficult sequences, including sequences with high complexity, repeats, or secondary structure, and the challenges of large-scale plasmid and vector production, limit the reliability and turnaround of some projects. The competitive and commoditizing nature of standard gene synthesis and cloning, following the advances and spread of technology, exerts price pressure, particularly for standard research-use services. The reliance on skilled molecular biology expertise and the shortage of skilled professionals constrain capacity. The variability of turnaround and quality across providers and projects, and the dependence of downstream research on the accuracy of the constructs, require quality assurance and verification. Intellectual property and the licensing of cloning technologies and vectors add complexity, and the requirement for research-use restrictions on some vectors and technologies constrains commercial use. The concentration of high-value therapeutic and good manufacturing practice services among providers with the capability and capacity limits the participation of smaller providers in the highest-value segments. Together, these factors moderate the pace and scope of growth and require providers to demonstrate quality, capability, compliance, and value to sustain growth.

DNA and Gene Cloning Services Market Segment Analysis

The global DNA and gene cloning services market is segmented by service type (gene synthesis, molecular cloning and sub cloning, vector construction and mutagenesis, and plasmid preparation and others), by application (drug discovery and development, synthetic biology, academic and basic research, and others), by grade (research-use, good manufacturing practice and clinical grade), and by end-users (pharmaceutical and biotechnology companies, academics and research institutes, contract research and manufacturing organizations, and others) by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Service Type

Dominant Subsegment: Gene Synthesis.

The gene synthesis category is expected to dominate the market. The gene synthesis segment accounted for a 38% share of the DNA and gene cloning services market in 2025. Gene synthesis, in which custom DNA sequences are synthesized de novo without a physical template, is the leading service type because it is the foundational service on which cloning, vector construction, and downstream applications depend, and it has grown with the advance of synthesis technology and the expansion of applications. The dominance of the segment reflects the foundational role of gene synthesis in providing custom DNA, the advance of synthesis technology that has expanded throughput and reduced cost, and the breadth of applications that begin with synthesized genes. Providers synthesize custom genes with sequence optimization and error correction, delivering synthesized DNA cloned into vectors and ready for expression, and gene synthesis is integrated with cloning, codon optimization, and vector construction. The advances in silicon-chip and high-throughput synthesis, the reduction of cost, and the expansion of applications in research, synthetic biology, and therapeutics drive the gene synthesis segment. While molecular cloning and subcloning, vector construction and mutagenesis, and plasmid preparation are essential and integrated services, the foundational role, technological advance, and breadth of application of gene synthesis sustain the leadership of the gene synthesis segment across the forecast period.

By Application

Dominant Subsegment: Drug Discovery and Development.

The drug discovery and development category is expected to dominate the market. The drug discovery and development segment accounted for a 36% share of the DNA and gene cloning services market in 2025. Drug discovery and development, encompassing the discovery and development of biologics, gene-based therapeutics, and small molecules, is the leading application because it is the largest and highest-value use of gene synthesis and cloning, beginning the development of the antibodies, proteins, vaccines, and gene and cell therapies that dominate the pipeline. The dominance of the segment reflects the centrality of gene synthesis and cloning to the discovery and development of biologics and gene-based therapeutics, the growth of the therapeutic pipeline, and the value of pharmaceutical and biotechnology demand. The development of biologics and gene-based therapeutics begins with the synthesis and cloning of target sequences, the construction of expression vectors, and the production of plasmid DNA, and providers support drug discovery and development from research through clinical stages. The growth of the biologics and gene therapy pipeline, the value of therapeutic development, and the dependence of drug discovery on gene synthesis and cloning drive the segment. While synthetic biology, academic research, diagnostics, and industrial applications are significant, the scale, value, and growth of drug discovery and development sustain the leadership of the drug discovery and development segment across the forecast period.

DNA and Gene Cloning Services Market Region Analysis

Dominant Region: North America

North America accounted for a 41% share of the global DNA and gene cloning services market in 2025, representing the highest regional market share globally. The leadership of the region reflects the advanced biotechnology and pharmaceutical industry, the concentration of gene synthesis and cloning providers, the strength of research funding, and the growth of cell and gene therapy. The United States is the largest national market, supported by the concentration of biotechnology and pharmaceutical companies, the extensive research funding for genomics and biomedical research, the presence and capacity of the leading gene synthesis and cloning providers, and the growth of cell and gene therapy and biologics development. The advanced healthcare and research infrastructure, the strong presence of biotechnology firms, the significant funding for recombinant DNA research, and the demand for gene synthesis and cloning from the therapeutic pipeline drive the adoption of services, and the leading providers operate extensive capacity in the region. The advanced industry, the concentration of providers, the research funding, and the growth of therapeutics reinforce the leadership of the region. The combination of industry strength, provider capacity, research funding, and therapeutic growth sustains the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region combines the rapid growth of its biotechnology and pharmaceutical industry, the expansion of research and manufacturing capacity, the presence of gene synthesis and cloning providers, and the growth of research funding, which drives the fast growth of the market. China, India, Japan, and South Korea are the principal national markets, supported by the rapid growth of biotechnology and pharmaceutical research and development, the expansion of contract research and manufacturing, the presence and growth of gene synthesis and cloning providers, and the increase in research funding and biomedical research. The growth of the biotechnology industry, the expansion of research and therapeutic development, and the growth of gene synthesis and cloning capacity enlarge the demand for services. As the biotechnology and pharmaceutical industry grows, as research and manufacturing expand, and as gene synthesis and cloning capacity grows, the region increases its demand and provision of services from a growing base, and the scale of the industry and research expansion creates substantial long-term demand. The combination of industry growth, research expansion, provider presence, and funding growth positions Asia-Pacific as the fastest-growing regional market, and it attracts investment and the expansion of global and regional providers.

Regional Commentary

North America

North America leads the market, supported by the advanced biotechnology and pharmaceutical industry, the concentration of gene synthesis and cloning providers, the strength of research funding, and the growth of cell and gene therapy. The United States dominates the region through its concentration of biotechnology and pharmaceutical companies, extensive research funding, and the capacity of the leading providers. The growth of biologics and gene therapy development sustains demand.

Europe

Europe is a substantial market shaped by a strong biotechnology and pharmaceutical industry, the presence of providers including Eurofins and Merck, and the growth of research and therapeutic development. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, supported by the biotechnology and pharmaceutical industry, research funding, and the growth of biologics and gene therapy. Demand is sustained by therapeutic development, research, and the outsourcing of molecular biology.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by the rapid growth of biotechnology and pharmaceutical research, the expansion of research and manufacturing capacity, and the growth of gene synthesis and cloning providers across China, India, Japan, and South Korea. Industry growth, research expansion, and provider growth sustain rapid growth, and the region attracts investment and the expansion of global and regional providers.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as biotechnology research and healthcare investment grow. Growth is supported by the growth of research, the expansion of biotechnology, and the increasing use of gene synthesis and cloning services, though research capacity and access vary by market. Providers pursue these markets through gene synthesis and cloning services and global logistics suited to growing research activity.

DNA and Gene Cloning Services Market Competitive Landscape

The global DNA and gene cloning services market is classified as Fragmented. A group of gene synthesis and molecular biology service providers holds a substantial share of the market, while DNA synthesis technology companies, specialty cloning providers, and regional providers compete on technology, quality, price, and turnaround. Competition centers on the throughput and cost of synthesis, the accuracy and quality of constructs, the breadth of services from synthesis to good manufacturing practice production, the selection of vectors and technologies, turnaround, and biosecurity and compliance; technology advances, capacity investment, and consolidation intensify the contest. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Fragmented, with a group of gene synthesis and molecular biology service providers holding a substantial share, alongside DNA synthesis technology companies, specialty cloning providers, and regional providers.
• Leading players: GenScript, Thermo Fisher Scientific, Twist Bioscience, and Integrated DNA Technologies lead in gene synthesis and cloning; Azenta through GENEWIZ and Eurofins lead in molecular biology services, and ATUM, Takara Bio, Merck, and Macrogen contest synthesis, cloning, and regional services.
• Geographic reach: The leading providers operate global synthesis, cloning, and logistics capacity, with concentration in North America and expanding presence in Europe and Asia-Pacific.
• Product portfolio strength: Competitive advantage rests on the breadth from gene synthesis and cloning to vector construction and good manufacturing practice plasmid production, the selection of vectors and technologies, and the throughput, accuracy, and turnaround of the services.
• Pipeline strength: Development is concentrated in synthesis technology and throughput, error correction and accuracy, artificial intelligence design, good manufacturing practice capacity, and biosecurity compliance.
• Strategic partnerships: Collaboration spans partnerships between synthesis technology and service companies, alliances with pharmaceutical and synthetic biology companies, and licensing of DNA technologies.
• M&A activity: Consolidation has shaped the field, with larger players acquiring synthesis, cloning, and technology companies to enhance capability and capacity, and the field includes large diversified companies alongside specialist providers.
• Innovation focus: Innovation is shifting toward higher-throughput and lower-cost synthesis, error correction and accuracy, artificial intelligence and automated design, good manufacturing practice and clinical-grade services, and biosecurity.
• Regulatory standing: Compliance with biosecurity screening under the harmonized screening protocol of the International Gene Synthesis Consortium and the framework for nucleic acid synthesis screening, good manufacturing practice for clinical-grade services, and export control are decisive competitive credentials and a principal axis of competition and responsibility among the leaders.

DNA and Gene Cloning Services Market Recent Developmental Activities

In April 2024, the White House Office of Science and Technology Policy issued the framework for nucleic acid synthesis screening, establishing expectations for the screening of synthetic nucleic acid sequences and customers to prevent misuse. Strategic significance: the framework reinforced the biosecurity obligations of gene synthesis providers and shaped the screening and compliance of the industry.

In May 2024, Twist Bioscience Corporation launched multiplexed gene fragments, enabling the pooled synthesis of DNA fragments and supporting high-throughput screening. Strategic significance: the launch advanced high-throughput gene synthesis and supported synthetic biology and screening applications.

DNA and Gene Cloning Services Market Segmentation

DNA and Gene Cloning Services Market Assessment by Service Type

• Gene Synthesis
• Molecular Cloning and Subcloning
• Vector Construction and Mutagenesis
• Plasmid Preparation and Others

DNA and Gene Cloning Services Market Assessment by Application

• Drug Discovery and Development
• Synthetic Biology
• Academic and Basic Research
• Others

DNA and Gene Cloning Services Market Assessment by End-User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research and Manufacturing Organizations
• Others

DNA and Gene Cloning Services Market Assessment by Grade

• Research-Use
• Good Manufacturing Practice and Clinical-Grade

DNA and Gene Cloning Services Market Assessment by Geography

• North America
• United States DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Canada DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Mexico DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Europe
• Germany DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• United Kingdom DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• France DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Italy DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Spain DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Rest of Europe DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Asia-Pacific
• China DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Japan DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• India DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Australia DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• South Korea DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Rest of Asia-Pacific DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Rest of the World
• Middle East DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• Africa DNA and Gene Cloning Services Market Size in USD million (2023-2034)
• South America DNA and Gene Cloning Services Market Size in USD million (2023-2034)

Key Takeaways from the DNA and Gene Cloning Services Market Report Study

• Market size analysis for the current DNA and gene cloning services market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key service and technology developments, launches, partnerships, and investments that happened over the last 3 years.
• Key companies dominating the global DNA and gene cloning services market.
• Various opportunities available for competitors in the DNA and gene cloning services market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current DNA and gene cloning services market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for DNA and gene cloning services market growth in the future?

Target audience who can benefit from this DNA and gene cloning services market report study

• Gene synthesis, molecular biology, and DNA cloning service providers
• Research organizations and consulting companies
• Gene synthesis and synthetic biology-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Pharmaceutical, biotechnology, and research organizations dealing in gene synthesis and cloning
• Various end-users who want to know more about the DNA and gene cloning services market and the latest technological developments in the DNA and gene cloning services market.

Frequently Asked Questions:

Q1. At what rate is the DNA and gene cloning services market expected to grow?

The global DNA and gene cloning services market is projected to grow at a compound annual growth rate of 15.7% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the DNA and gene cloning services market?

The global DNA and gene cloning services market was valued at USD 4.20 billion in 2025 and is projected to reach USD 15.60 billion by 2034.

Q3. Which region dominates the DNA and gene cloning services market?

North America dominated the DNA and gene cloning services market with a 41% share in 2025, driven by the advanced biotechnology and pharmaceutical industry, the concentration of gene synthesis and cloning providers, the strength of research funding, and the growth of cell and gene therapy. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the rapid growth of biotechnology and pharmaceutical research and the expansion of gene synthesis and cloning capacity across China, India, Japan, and South Korea.

Q4. What are the key factors driving growth in the DNA and gene cloning services market?

The principal drivers are the growth of biologics and gene-based therapeutics; the expansion of synthetic biology and cell and gene therapy; the advance of gene synthesis and cloning technology, including silicon-chip synthesis and automation; the outsourcing of molecular biology to specialized providers; the growth of good manufacturing practice cloning and plasmid production; and the adoption of artificial intelligence and automated design platforms.

Q5. Who are the major players in the DNA and gene cloning services market?

The market is fragmented and led by GenScript Biotech Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation, Integrated DNA Technologies, Inc., and Azenta, Inc., alongside ATUM, Eurofins Scientific SE, Takara Bio Inc., Merck KGaA, and Macrogen, Inc. Additional participants including OriGene Technologies, Inc., Bioneer Corporation, Synbio Technologies, and Quintara Biosciences compete across gene synthesis, cloning, and molecular biology services.

Table of Contents

1. DNA and Gene Cloning Services Market Introduction

• 1.1. Scope of the Report
• 1.2. Market Segmentation
• 1.3. Market Overview at a Glance

2. DNA and Gene Cloning Services Market Executive Summary

• 2.1. Key Highlights and Market Snapshot

3. DNA and Gene Cloning Services Market Key Factors Analysis

• 3.1. Market Drivers
  • 3.1.1. Growth of Biologics and Gene-Based Therapeutics
  • 3.1.2. Expansion of Synthetic Biology and Cell and Gene Therapy
  • 3.1.3. Advances in Gene Synthesis and Cloning Technology
  • 3.1.4. Outsourcing, Good Manufacturing Practice Cloning, and Artificial Intelligence Design
• 3.2. Market Restraints
  • 3.2.1. Complexity and Cost of High-Value and Clinical-Grade Services
  • 3.2.2. Biosecurity Screening and Compliance
  • 3.2.3. Price Pressure and Technical and Workforce Constraints
• 3.3. Market Opportunities
  • 3.3.1. Cell and Gene Therapy and Good Manufacturing Practice Services
  • 3.3.2. Emerging Markets and Synthesis Technology

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory and Biosecurity Analysis

• 5.1. The United States
• 5.2. Europe
• 5.3. Japan
• 5.4. China

6. DNA and Gene Cloning Services Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. DNA and Gene Cloning Services Market Assessment

• 7.1. By Service Type
  • 7.1.1. Gene Synthesis
  • 7.1.2. Molecular Cloning and Subcloning
  • 7.1.3. Vector Construction and Mutagenesis
  • 7.1.4. Plasmid Preparation and Others
• 7.2. By Application
  • 7.2.1. Drug Discovery and Development
  • 7.2.2. Synthetic Biology
  • 7.2.3. Academic and Basic Research
  • 7.2.4. Others
• 7.3. By End-User
  • 7.3.1. Pharmaceutical and Biotechnology Companies
  • 7.3.2. Academic and Research Institutes
  • 7.3.3. Contract Research and Manufacturing Organizations
  • 7.3.4. Others
• 7.4. By Grade
  • 7.4.1. Research-Use
  • 7.4.2. Good Manufacturing Practice and Clinical-Grade
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.1.2. Canada DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.1.3. Mexico DNA and Gene Cloning Services Market Size in USD million (2023-2034)
  • 7.5.2. Europe
    • 7.5.2.1. Germany DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.2.2. United Kingdom DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.2.3. France DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.2.4. Italy DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.2.5. Spain DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.2.6. Rest of Europe DNA and Gene Cloning Services Market Size in USD million (2023-2034)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.3.2. Japan DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.3.3. India DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.3.4. Australia DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.3.5. South Korea DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.3.6. Rest of Asia-Pacific DNA and Gene Cloning Services Market Size in USD million (2023-2034)
  • 7.5.4. Rest of the World
    • 7.5.4.1. Middle East DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.4.2. Africa DNA and Gene Cloning Services Market Size in USD million (2023-2034)
    • 7.5.4.3. South America DNA and Gene Cloning Services Market Size in USD million (2023-2034)

8. DNA and Gene Cloning Services Market Competitive Landscape

• 8.1. Competitive Analysis
• 8.2. Company Share Analysis (Premium Offering)

9. DNA and Gene Cloning Services Market Startup Funding and Investment Trends

10. DNA and Gene Cloning Services Market Company and Service Profiles

• 10.1. GenScript Biotech Corporation
  • 10.1.1. Company Overview
  • 10.1.2. Company Snapshot
  • 10.1.3. Financial Overview
  • 10.1.4. Service Portfolio
  • 10.1.5. Strategic Initiatives / Entropy
• 10.2. Thermo Fisher Scientific Inc.
  • 10.2.1. Company Overview
  • 10.2.2. Company Snapshot
  • 10.2.3. Financial Overview
  • 10.2.4. Service Portfolio
  • 10.2.5. Strategic Initiatives / Entropy
• 10.3. Twist Bioscience Corporation
  • 10.3.1. Company Overview
  • 10.3.2. Company Snapshot
  • 10.3.3. Financial Overview
  • 10.3.4. Service Portfolio
  • 10.3.5. Strategic Initiatives / Entropy
• 10.4. Integrated DNA Technologies, Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Snapshot
  • 10.4.3. Financial Overview
  • 10.4.4. Service Portfolio
  • 10.4.5. Strategic Initiatives / Entropy
• 10.5. Azenta, Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Company Snapshot
  • 10.5.3. Financial Overview
  • 10.5.4. Service Portfolio
  • 10.5.5. Strategic Initiatives / Entropy
• 10.6. ATUM
  • 10.6.1. Company Overview
  • 10.6.2. Company Snapshot
  • 10.6.3. Financial Overview
  • 10.6.4. Service Portfolio
  • 10.6.5. Strategic Initiatives / Entropy
• 10.7. Eurofins Scientific SE
  • 10.7.1. Company Overview
  • 10.7.2. Company Snapshot
  • 10.7.3. Financial Overview
  • 10.7.4. Service Portfolio
  • 10.7.5. Strategic Initiatives / Entropy
• 10.8. Takara Bio Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Snapshot
  • 10.8.3. Financial Overview
  • 10.8.4. Service Portfolio
  • 10.8.5. Strategic Initiatives / Entropy
• 10.9. Merck KGaA
  • 10.9.1. Company Overview
  • 10.9.2. Company Snapshot
  • 10.9.3. Financial Overview
  • 10.9.4. Service Portfolio
  • 10.9.5. Strategic Initiatives / Entropy
• 10.10. Macrogen, Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Company Snapshot
  • 10.10.3. Financial Overview
  • 10.10.4. Service Portfolio
  • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us